Predictors of Bleeding Evaluation in Adult Hematologic Patients with Bleeding Tendencies

The ProBE-AHP study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON27868

Enrollment

300

Registered

2021-07-28

Start date

2021-07-28

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

von Willebrand disease, platelet function disorders, coagulation factor deficiencies, fibrinolysis disorders, bleeding of unknown cause

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Age > 18 years; Signed informed consent; Patients with (suspected) bleeding tendency.

Exclusion criteria

Exclusion criteria: Pregnancy (or lactating); Active bleeding due to medical interventions or surgical/obstetrical causes. The use of medication which may interfere with diagnostic tests.

Design outcomes

Primary

Measure	Time frame
To assess the diagnostic parameters: sensitivity, specificity, negative predictive value, positive predictive value, likelihood ratio of the experimental haemostatic tests by comparing them to our standard diagnostic algorithm (MUMC protocol) as gold standard.	—

Secondary

Measure	Time frame
Number of patients with discrepant results in different aggregations assays (multiplate vs. LTA); Discrepant results between PFA and vWF antigen/activity; Optimizing cost-effectiveness in diagnostic strategies.	—

Contacts

Public ContactFloor Heubel-Moenen

MUMC+

floor.moenen@mumc.nl0433876543

Outcome results